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Abstract: A 61-year-old woman with lung cancer developed delayed transfusion-related acute 
lung injury (TRALI) syndrome after transfusion of plasma- and leukoreduced red blood cells 
(RBCs) for gastrointestinal bleeding due to intestinal metastasis. Acute lung injury (ALI) recurred 
31 days after the first ALI episode. Both ALI episodes occurred 48 hours after   transfusion. 
Laboratory examinations revealed the presence of various antileukocyte antibodies including 
antiplatelet antibody in the recipient’s serum but not in the donors’ serum. The authors speculate 
that antiplatelet antibodies can have an inhibitory effect in the recipient, which can modulate the 
bona fide procedure of ALI and lead to a delay in the onset of ALI. This case illustrates the crucial 
role of a recipient’s platelets in the development of TRALI.
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Introduction
Transfusion-related acute lung injury (TRALI) is a clinical syndrome associated with 
blood transfusions and is typically characterized by the sudden onset of dyspnea due 
to bilateral noncardiogenic pulmonary edema.1 Although classic TRALI is defined as 
acute lung injury (ALI) that occurs within 6 hours following transfusion, late-onset ALI 
associated with blood transfusion has also been observed clinically. It is proposed that 
this condition is an independent disease entity termed “delayed TRALI syndrome.”2 
A recent laboratory investigation using the two-event animal model proposed that a 
TRALI event could be halted by the depletion of platelets from the recipient animal,3 
and in addition, there are a few reports on the participation of platelets in TRALI.4,5 
However, the clinical evidence that supports this rationale is poorly understood. In 
this report, a patient who experienced a recurrence of delayed TRALI syndrome 
is presented. Antiplatelet antibodies were found in the recipient rather than in the 
donors.
Case report
The patient was a 61-year-old woman who was diagnosed with advanced nonsmall-
cell lung cancer with multiple brain metastases. She received systemic chemotherapy 
(carboplatin + paclitaxel) for lung cancer. However, febrile neutropenia (38.5°C, 
neutrophil 753/µL, C-reactive protein 41.50 mg/dL) and rapidly progressing anemia 
(Hb 5.2 g/dL) due to intestinal tract bleeding developed after chemotherapy. She 
was immediately administered two bags (600 mL) of plasma- and leukoreduced red 
blood cells (RBCs) on hospital day 1. No apparent complications were observed 
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within 6 hours after transfusion; however, 48 hours after 
the transfusion, sudden development of dyspnea and rapid 
progression of hypoxemia were observed. A chest radiograph 
showed bilateral diffuse pulmonary infiltrates without 
cardiomegaly (Figure 1A). B-type natriuretic peptide levels 
were within the normal limits. There was no evidence of 
microbial, Pneumocystis, tubercular, or fungal infection 
in the lungs. Methylprednisolone sodium succinate was 
administered for pulmonary edema, but pulmonary infiltrates 
and hypoxemia continued to worsen (Figure 1B). On day 23, 
chest radiography showed a significant improvement in 
pulmonary shadows (Figure 1C). However, bleeding from 
the intestinal tract continued, and two additional transfusions, 
each comprising two bags of RBCs, were required. No 
adverse events were associated with the two additional 
transfusions. On day 32, an additional transfusion of two 
bags of RBCs was performed and on day 34, there was 
a rapid deterioration of the respiratory condition again. 
Bilateral pulmonary infiltrates were again observed on a 
chest radiograph (Figure 1D). The patient died of multiple 
organ failure the next day. An autopsy was performed, and the 
pathological findings of the lungs indicated diffuse alveolar 
damage with hyaline membrane formation (Figure 2A).
To elucidate the contribution of platelets to ALI, we tried 
an immunohistochemical staining for the platelet using anti-
CD41 antibody against the pulmonary specimen obtained 
from the autopsy. The results clearly demonstrated the 
sequestration of platelets in the patient’s lung (Figure 2B). 
These findings strongly suggested the contribution of platelets 
to the pathogenesis of ALI in this case. Antileukocyte 
antibodies were not detected in the serum of donors from 
whom the blood products that led to both of the ALI episodes 
were obtained. However, antiplatelet Immunoglobulin M 
antibodies, in addition to the various antileukocyte antibodies 
(anti-human leukocyte antigen (HLA)-I, anti-HLA-II, 
antimonocyte, and unclassified antineutrophil antibody), 
were detected in the serum of the recipient.
Discussion
Classic TRALI is defined as an ALI that occurs within 6 hours 
after blood transfusion.6 However, this diagnostic criterion for 
classic TRALI was not met in our case because the two ALI 
episodes did not occur within 6 hours after the correspond-
ing transfusions. A recent report on the two-event animal 
model revealed that the environmental status of the recipient 
can affect the procedure in TRALI.3 Looney et al described 
that platelets in the circulation of the recipient are essential 
for developing ALI and act as terminal effector cells.3 The 
pathological findings also showed marked sequestration of 
platelets in the lung in which ALI developed. However, some 
antiplatelet antibodies have been shown to directly activate 
platelets.7,8
Platelets have been shown to contain members of the 
chemokine family of the C-C class, such as regulated on 
activation, normal T-cell expressed, and secreted and monocyte 
chemotactic peptide-3, as well as the CXC class, such as 
interleukin-8 and epithelial neutrophil-activating peptide-78.9 
Moreover, recent studies have shown that human platelets 
Figure 1 Chest radiographs. (A) Onset of the first transfusion-related acute lung 
injury episode on hospital day 3. (B) At the initiation of mechanical ventilation 
on day 9. (C) A clear chest radiograph on day 23. (D) Onset of the second first 
transfusion-related acute lung injury episode on hospital day 34.
Figure 2 Pathological findings. (A and B) Findings of histological examination of the 
lung: (A) result of hematoxylin and eosin staining revealed diffuse alveolar damage 
with hyaline membrane formation (×200), (B) result of immunostaining for CD41 
demonstrated the sequestration of platelets in the lung (×200). (C) Positive control 
of immunostaining for CD41 (normal bone marrow) (×200).
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express Toll-like receptor 410 and can sequestrate in the lung 
in response to lipopolysaccharide (LPS) in a neutrophil-
dependent manner.11,12 Taken together, these findings suggest 
that circulating platelets contribute to the development of 
TRALI throughout the whole process. In the case documented 
here, antileukocyte antibodies were not found in the donors, 
but antiplatelet antibodies were observed in serum from the 
recipient. It is hypothesized that severe bacterial infection 
associated with systemic chemotherapy plays a role in LPS-
priming, and the transfusion of stored RBCs, which can contain 
any biological response modifier (eg, lysophosphatidylcholine, 
arachidonic acid, or hydroxyeicosatetraenoic acid), acts as 
a “second hit” initiating TRALI.13 However, antiplatelet 
antibodies in the recipient might inhibit intra-alveolar platelet 
recruitment, resulting in a delay of platelet sequestration. 
Consequently, it is considered that this delay of platelet 
sequestration due to antiplatelet antibodies could cause a 
48-hour eclipse time from the corresponding blood transfusion 
to the development of ALI. The present case report suggests 
an important role for the recipient’s platelets and antiplatelet 
autoantibodies in the development of TRALI (Figure 3). These 
clinical findings could represent modulation of a TRALI event 
by environmental factors in the recipient, rather than in the 
donors.
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Figure 3 Rationale of delayed transfusion-related acute lung injury. In delayed TRALI, antiplatelet autoantibodies interfere with the release of IL-8 and ENA-78, and platelet-
neutrophil aggregation and secretion of TXA2, resulting in a delay of onset of acute lung injury.
Abbreviations: ENA-78, epithelial neutrophil-activating peptide (ENA)-78; IL-8, interleukin (IL)-8; LPS, lipopolysaccharide; TRALI, transfusion-related acute lung injury; 
TRL-4, toll-like receptor 4; TXA2, thromboxane A2.
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